AstraZeneca Revenue Hurt as Demand for COVID-19 Treatments Slumps; Stock Drops

Key TakeawaysAstraZeneca PLC missed profit forecasts Thursday as its fourth-quarter sales were slowed by falling demand for COVID-19 vaccines and medicines.The drug maker's revenue was also negatively affected by generic competition in Japan for its Nexium acid reflux treatment.AstraZeneca's American Depositary Receipts (ADRs) dropped to their lowest level in 16 months after the earnings were released Thursday.AstraZeneca PLC's (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the d ...